Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial Cyriel Y Ponsioen, E Joline de Groof , Emma J Eshuis , Tjibbe J Gardenbroek , Patrick M M Bossuyt, Ailsa Hart, Janindra Warusavitarne, Christianne J Buskens, Ad A van Bodegraven, Menno A Brink, Esther C J Consten, Bart A van Wagensveld, Marno C M Rijk, Rogier M P H Crolla, Casper G Noomen, Alexander P ..
Tag : anti-TNF
Infliximab with Azathiopurine in Ulcerative Colitis Related articles:*Acute severe colitis*Mild-to-Moderate Ulcerative Colitis*Probiotics in Ulcerative Colitis*Methotrexate in Ulcerative Colitis*Infliximab Ulcerative Colitis*Acute severe colitis: Accelerated induction Infliximab*Adalimumab in Ulcerative Colitis (ULTRA studies)*Golimumab in Ulcerative Colitis*Vedolizumab vs Adalimumab Ulcerative Colitis*Vedolizumab Ulcerative Colitis*Tofacitinib (OCTAVE Ulcerative Colitis)*Ustekinumab (Ulcerative colitis)*Acute severe colitis: Infliximab vs ciclosporin (CONTRUCT) Infliximab Azathiopurine combination therapy in ..
Related articles:*Acute severe colitis*Mild-to-Moderate Ulcerative Colitis*Probiotics in Ulcerative Colitis*Methotrexate in Ulcerative Colitis*Infliximab Ulcerative Colitis*Infliximab with Azathiopurine (Ulcerative Colitis)*Acute severe colitis: Accelerated induction Infliximab*Golimumab in Ulcerative Colitis*Vedolizumab vs Adalimumab Ulcerative Colitis*Vedolizumab Ulcerative Colitis*Tofacitinib (OCTAVE Ulcerative Colitis)*Ustekinumab (Ulcerative colitis)*Acute severe colitis: Infliximab vs ciclosporin (CONTRUCT) Adalimumab for induction of clinical remission in moderately to severely active ulcerative ..
Related articles:*Acute severe colitis*Mild-to-Moderate Ulcerative Colitis*Probiotics in Ulcerative Colitis*Methotrexate in Ulcerative Colitis*Infliximab Ulcerative Colitis*Infliximab with Azathiopurine (Ulcerative Colitis)*Acute severe colitis: Accelerated induction Infliximab*Adalimumab in Ulcerative Colitis (ULTRA studies)*Vedolizumab vs Adalimumab Ulcerative Colitis*Vedolizumab Ulcerative Colitis*Tofacitinib (OCTAVE Ulcerative Colitis)*Ustekinumab (Ulcerative colitis)*Acute severe colitis: Infliximab vs ciclosporin (CONTRUCT) Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With ..
Infliximab with Azathiopurine (Crohn) Related articles (Crohn):*Azathioprine Crohn*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Methotrexate (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Adalimumab with immunomodulator (Crohn)*Ustekinumab (UNITI trial – Crohn – 2016)*Vedolizumab (GEMINI II – Crohn – 2013) Infliximab, Azathioprine, or Combination Therapy for Crohn’s Disease Jean Frédéric ..
Infliximab with Methotrexate (Crohn) Related articles (Crohn):*Azathioprine Crohn*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Azathiopurine (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Adalimumab with immunomodulator (Crohn)*Ustekinumab (UNITI trial – Crohn – 2016)*Vedolizumab (GEMINI II – Crohn – 2013) Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in ..
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease Nicholas A Kennedy, Graham A Heap, Harry D Green, Benjamin Hamilton, Claire Bewshea, Gareth J Walker, Amanda Thomas, Rachel Nice, Mandy H Perry, Sonia Bouri, Neil Chanchlani, Neel M Heerasing, Peter Hendy, SimengLin, Daniel R Gaya, J R Fraser Cummings, Christian P ..
Infliximab switch to Adalimumab in Crohn Related articles (Crohn):*Azathioprine Crohn*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Azathiopurine (Crohn)*Infliximab with Methotrexate (Crohn)*Adalimumab (CLASSIC & CHARM trial – Crohn)*Adalimumab with immunomodulator (Crohn)*Ustekinumab (UNITI trial – Crohn – 2016)*Vedolizumab (GEMINI II – Crohn – 2013) Background and Aims: In the 4-week GAIN clinical trial, adalimumab was efficacious ..
Bruce E. Sands, William J. Sandborn, Gert Van Assche, Milan Lukas, Jing Xu, Alexandra James, Brihad Abhyankar, Karen Lasch, Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy, Inflammatory Bowel Diseases, Volume 23, Issue 1, 1 January 2017, Pages 97–106, https://doi.org/10.1097/MIB.0000000000000979 Background ..
Effects of Withdrawal of Immunomodulators or Biologic Agents IBD Withdrawal of IBD (Inflammatory Bowel Disease) therapy; for example anti-TNF. 50% or more of patients with IBD who cease/stop therapy have a disease relapse. The decision to withdraw a drug should be made for each individual based on patient preference, disease markers, consequences of relapse, safety, ..
Adalimumab in Crohn Related articles (Crohn):*Azathioprine Crohn*Methotrexate in Crohn*Infliximab in Crohn (ACCENT I)*Infliximab with Azathiopurine (Crohn)*Infliximab with Methotrexate (Crohn)*Infliximab switch to Adalimumab in Crohn (GAIN/ADHERE trial)*Adalimumab with immunomodulator (Crohn)*Ustekinumab (UNITI trial – Crohn – 2016)*Vedolizumab (GEMINI II – Crohn – 2013) Classic-I trial induction 2006 Background & aims: Tumor necrosis factor blockade has been shown ..
Recent Comments